1,301 research outputs found

    Boydbolt, a positive-latch, simple-release fastener

    Get PDF
    Fastener /Boydbolt/ has recently been designed to furnish positive lock and release characteristics that positively prevent accidental adverse functions of lock or release

    Tractors on upland farms in North Louisiana

    Get PDF

    Polygamy and child mortality: Historical and modern evidence from Nigeria’s Igbo

    Get PDF
    We use historical and modern data on the Igbo ethnic group in Nigeria to assess the relationship between polygamy and child mortality. We examine several possible channels for this correlation, and test its sensitivity to observable characteristics of individuals, households, and regions in order to infer the scope for selection on unobservables to drive the polygamy-child mortality correlation. We find a statistically significant positive relationship between polygamy and child mortality in the modern period, and a statistically insignificant positive relationship in the historical data. Although there is a limited role for polygamist-specific intra-household dynamics and behavioral practices in shaping the mortality of children in such households, the sensitivity of the polygamy-child mortality correlation is consistent with an important role for selection into polygamy, particularly on unobservable characteristics

    The Inclusion of In-Plane Stresses in Delamination Criteria

    Get PDF
    A study of delamination is performed including strength of materials and fracture mechanics approaches with emphasis placed on methods of delamination prediction. Evidence is presented which supports the inclusion of the in-plane stresses in addition to the inter-laminar stress terms in delamination criteria. The delamination can be modeled as a resin rich region in between ply sets. The entire six component stress state in this resin layer is calculated through a finite element analysis and inputted into a new Modified Von Mises Delamination Criterion. This criterion builds onto previous criteria by including all six stress components. The MVMDC shows improved correlation to experimental data

    Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: Increasingly successful application to older patients

    Get PDF
    AbstractNon-Hodgkin lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with widely varying biological, histological, and clinical features. For the B cell NHLs, great progress has been made due to the addition of monoclonal antibodies and, more recently, other novel agents including B cell receptor signaling inhibitors, immunomodulatory agents, and proteasome inhibitors. Autologous hematopoietic cell transplantation (auto-HCT) offers the promise of cure or prolonged remission in some NHL patients. For some patients, however, auto-HCT may never be a viable option, whereas in others, the disease may progress despite auto-HCT. In those settings, allogeneic HCT (allo-HCT) offers the potential for cure. Over the past 10 to 15 years, considerable progress has been made in the implementation of allo-HCT, such that this approach now is a highly effective therapy for patients up to (and even beyond) age 75 years. Recent advances in conventional lymphoma therapy, peritransplantation supportive care, patient selection, and donor selection (including the use of alternative hematopoietic cell donors), has allowed broader application of allo-HCT to patients with NHL. As a result, an ever-increasing number of NHL patients over age 60 to 65 years stand to benefit from allo-HCT. In this review, we present data in support of the use of allo-HCT for patients with diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. These histologies account for a large majority of allo-HCTs performed for patients over age 60 in the United States. Where possible, we highlight available data in older patients. This body of literature strongly supports the concept that allo-HCT should be offered to fit patients well beyond age 65 and, accordingly, that this treatment should be covered by their insurance carriers
    • …
    corecore